STEAP1 and posterior cortical atrophy: Similarly, AMG-509, another BiTE targeting the PCa cell-surface antigen STEAP1, has shown significant efficacy against cancer cells in pre-clinical xenograft models and is currently being evaluated for treatment efficacy in patients (NCT04221542) (Table 1).